Senolytx was born in the year 2017, fruit of the research led by Manuel Serrano. Selenolytic Therapeutics focuses on the removal of senescent cells for the treatment of diseases related to aging, like fibrotic diseases such as idiopatic pulmonar fibrosis (IPF).
